Marlborough pharma names new CEO as its diabetes drug moves to commercialization

Marlborough-based drug manufacturer TheracosBio has named Brian Connelly as its new president and CEO. 

Connelly joins the company after it emerged from clinical trial phases in January to commercialize its drug, Brenzavvy, a type 2 diabetes treatment approved by the U.S. Food and Drug Administration. TheracosBio named its first CFO in March.

Connelly has two decades of experience in law and business in the biopharmaceutical industry, according to a Tuesday press release from the company. He is the co-founder of IncreVet, a Boston veterinary drug development firm that received FDA approval for a feline diabetes treatment. The firm was acquired by the parent company of TheracosBio, Theracos, Inc., in 2022.

TheracosBios’s previous CEO, Albert Collinson, is stepping down after being with the company from phase 1 clinical trials to commercial launch, according to the press release. He will remain an advisor to the company.

Connelly earned his bachelor’s degree from Boston College and his law degree from the George Washington University Law School in Washington, D.C.